Assignee
ABBVIE STEMCENTRX LLC
US·30 granted patents·27 pending applications·161 citations·filing 2014–2025
Top patents by PatentIndex Score
57 records- 0198US11033634B2Light chain variable regionsABBVIE STEMCENTRX LLC·Filed 2019·Granted Jun 15, 2021·6 cites·16 claims
- 0296US9937268B2Anti-DLL3 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Granted Apr 10, 2018·9 cites·30 claims
- 0396US9931421B2Methods of delivering DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Apr 3, 2018·9 cites·30 claims
- 0496US9931420B2Methods of making DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Apr 3, 2018·9 cites·30 claims
- 0596US9878053B2Methods of delivering DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 30, 2018·9 cites·30 claims
- 0696US9867887B1Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 16, 2018·9 cites·30 claims
- 0796US9861708B2Kits containing DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 9, 2018·9 cites·30 claims
- 0896US9855343B2Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 2, 2018·9 cites·30 claims
- 0996US9775916B1Anti-DLL3 antibody drug conjugates for treating cancerABBVIE STEMCENTRX LLC·Filed 2017·Granted Oct 3, 2017·9 cites·30 claims
- 1096US9770518B1Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Sep 26, 2017·9 cites·30 claims
- 1196US9764042B1Methods of making DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2017·Granted Sep 19, 2017·9 cites·30 claims
- 1295US10137204B2Anti-DLL3 antibody drug conjugates for treating cancerABBVIE STEMCENTRX LLC·Filed 2016·Granted Nov 27, 2018·8 cites·33 claims
- 1390US10478509B2Anti-DLL3 antibody drug conjugates for treating cancerABBVIE STEMCENTRX LLC·Filed 2018·Granted Nov 19, 2019·6 cites·30 claims
- 1489US10836831B2Anti-PTK7 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Granted Nov 17, 2020·3 cites·23 claims
- 1585US10035853B2Site-specific antibody conjugation methods and compositionsABBVIE STEMCENTRX LLC·Filed 2016·Granted Jul 31, 2018·13 cites·42 claims
- 1683US10308721B2Anti-DLL3 antibodies and drug conjugates for use in melanomaABBVIE STEMCENTRX LLC·Filed 2015·Granted Jun 4, 2019·7 cites·28 claims
- 1782US9914784B2PTK7 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Mar 13, 2018·3 cites·19 claims
- 1880US10934359B2Anti-BMPR1B antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Granted Mar 2, 2021·3 cites·9 claims
- 1980US10053511B2Anti-claudin antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2014·Granted Aug 21, 2018·5 cites·55 claims
- 2080US9993566B2SEZ6 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2014·Granted Jun 12, 2018·4 cites·41 claims
- 2178US10047163B2Multispecific constructsABBVIE STEMCENTRX LLC·Filed 2014·Granted Aug 14, 2018·3 cites·3 claims
- 2277US10533051B2Anti SEZ6 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Granted Jan 14, 2020·1 cites·17 claims
- 2377US9968687B2Anti-DLL3 antibody drug conjugatesABBVIE STEMCENTRX LLC·Filed 2014·Granted May 15, 2018·2 cites·59 claims
- 2477US2019247510A1Dll3 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 2576US10428156B2Anti-MFI2 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2015·Granted Oct 1, 2019·3 cites·32 claims
- 2675US10017565B2Modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Jul 10, 2018·2 cites·19 claims
- 2775US2019046656A1Dll3 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 2872US2025213714A1Anti-sez6 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2025·Application pending·0 cites
- 2971US10189910B2Anti-DPEP3 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Jan 29, 2019·1 cites·38 claims
- 3071US9777071B2Anti-DPEP3 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted Oct 3, 2017·1 cites·15 claims
- 3169US2021338831A1Anti-sez6 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2021·Application pending·0 cites
- 3268US11077203B2Anti-SEZ6 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2020·Granted Aug 3, 2021·0 cites·4 claims
- 3368US2021196834A1Anti-sez6 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 3467US2020181256A1Anti sez6 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 3559US2018237512A1Novel modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 3658US9969798B2Modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Granted May 15, 2018·0 cites·27 claims
- 3754US2021261670A1Novel anti-bmpr1b antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2021·Application pending·0 cites
- 3853US2018067120A1Identification and enrichment of cell subpopulationsABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 3952US2019225685A1Anti-dll3 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2019·Application pending·0 cites
- 4050US10087258B2Anti-CD324 monoclonal antibodies and uses thereofABBVIE STEMCENTRX LLC·Filed 2016·Granted Oct 2, 2018·0 cites·8 claims
- 4149US2019077876A1Novel anti-claudin antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 4249US2019022241A1Novel sez6 modulators and methods of useABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 4344US2019201542A1Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transitionABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 4443US2018346565A1Site-specific antibody conjugation methods and compositionsABBVIE STEMCENTRX LLC·Filed 2018·Application pending·0 cites
- 4542US2018243435A1Anti-dll3 antibody drug conjugates and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Application pending·0 cites
- 4641US2019016812A1Novel anti-tnfsf9 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Application pending·0 cites
- 4738US2019194319A1Anti-ascl1 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 4837US2019127476A1Novel anti-tnfrsf21 antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2017·Application pending·0 cites
- 4937US2018112004A1Engineered site-specific antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Application pending·0 cites
- 5037US2019083645A1Novel anti-claudin antibodies and methods of useABBVIE STEMCENTRX LLC·Filed 2016·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ABBVIE STEMCENTRX LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →